The ceramide synthase 5 (CERS5), also known as longevity assurance gene 3 (LASS5), is a key enzyme in sphingolipid metabolism, catalyzing the synthesis of C16-ceramides by linking sphingosine to a C16 fatty acyl-CoA. Ceramides, central bioactive lipids, regulate cellular processes like apoptosis, proliferation, and stress responses. Dysregulation of CERS5 has been implicated in metabolic disorders, cancer, and neurodegenerative diseases. For instance, elevated CERS5 expression is observed in certain cancers, promoting tumor growth and chemoresistance, while its deficiency is linked to insulin resistance and hepatic steatosis. Antibodies targeting CERS5 are essential tools for studying its expression, localization, and function in vitro and in vivo. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in elucidating tissue-specific roles of CERS5. Recent studies also explore CERS5 as a therapeutic target, with antibodies potentially serving as diagnostic or prognostic biomarkers. Research continues to unravel its interactions with signaling pathways (e.g., PI3K/AKT) and its influence on lipid raft dynamics. Overall, CERS5 antibodies are pivotal in advancing understanding of sphingolipid biology and its implications in disease mechanisms.